

1 **An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an**
2 **antiviral candidate for SARS-CoV-2**

3 **Authors and affiliations:** Lauren E Walker^{1,2*}, Richard FitzGerald², Geoffrey Saunders³, Rebecca
4 Lyon², Michael Fisher^{1,2}, Karen Martin³, Izabela Eberhart³, Christie Woods², Sean Ewings³, Colin Hale²,
5 Rajith KR Rajoli¹, Laura Else¹, Sujana Dilly-Penchala¹, Alieu Amara¹, David G Lalloo⁴, Michael Jacobs⁴,
6 Henry Pertinez¹, Parys Hatchard³, Robert Waugh³, Megan Lawrence³, Lucy Johnson³, Keira Fines³,
7 Helen Reynolds¹, Timothy Rowland², Rebecca Crook², Kelly Byrne⁴, Pavel Mozgunov⁵, Thomas Jaki⁵,
8 Saye Khoo¹, Andrew Owen¹, Gareth Griffiths³, Thomas E Fletcher^{2,4} on behalf of the AGILE platform

9 ¹University of Liverpool

10 ²Liverpool University Hospitals NHS Foundation Trust

11 ³Southampton Clinical Trials Unit, University of Southampton, Southampton UK

12 ⁴Liverpool School of Tropical Medicine

13 ⁵MRC Biostatistics Unit, University of Cambridge

14

15 **Author for correspondence:**

16 Dr Lauren E Walker
17 Institute of Systems, Molecular and Integrative Biology (ISMIB)
18 University of Liverpool
19 Block A: Waterhouse Building
20 1-5 Brownlow Street
21 Liverpool L69 3GL
22 Lauren.walker@liverpool.ac.uk
23 0151 794 5407

24

25

26 **Key words:** COVID-19, SARS-CoV-2, Coronavirus, Pharmacokinetics, Repurposing, Phase I

27

28 **Conflicts of interest statement**

29 AO is Director of Tandem Nano Ltd. AO has received research funding from ViiV, Merck, Janssen and
30 consultancy from Gilead, ViiV and Merck not related to the current paper. Ridgeback and
31 GlaxoSmithKline have provided funding to the AGILE phase I/II platform to evaluate SARS-CoV-2
32 candidates independently of the current trial. GG has received funding from Janssen-Cilag, Astra
33 Zeneca, Novartis, Astex, Roche, Heartflow, Celldex, BMS, BionTech, Cancer Research UK, NIHR,
34 British Lung Foundation, Unitaid, GSK for unrelated academic clinical trials and programme funding.
35 SK has received funding from Merck, ViiV, Janssen, Gilead for unrelated academic trials. No other
36 conflicts are declared by the authors.

37

38 **Funding**

39 This trial was funded by Unitaid as part of a supplement to project LONGEVITY in response to the
40 SARS-CoV-2 pandemic. AO also acknowledges research funding from EPSRC (EP/R024804/1);

41 EP/S012265/1), NIH (R01AI134091; R24AI118397), European Commission (761104). The authors also
42 acknowledge funding from Wellcome Trust [221590/Z/20/Z] and Medical Research Council
43 [MR/V028391/1] for the AGILE phase I/II platform trial.
44

45 **Abstract**

46 Repurposing approved drugs may rapidly establish effective interventions during a public health
47 crisis. This has yielded immunomodulatory treatments for severe COVID-19, but repurposed
48 antivirals have not been successful to date because of redundancy of the target *in vivo* or suboptimal
49 exposures at studied doses. Nitazoxanide is an FDA approved antiparasitic medicine, that
50 physiologically-based pharmacokinetic (PBPK) modelling has indicated may provide antiviral
51 concentrations across the dosing interval, when repurposed at higher than approved doses. Within
52 the AGILE trial platform (NCT04746183) an open label, adaptive, phase 1 trial in healthy adult
53 participants was undertaken with high dose nitazoxanide. Participants received 1500mg
54 nitazoxanide orally twice-daily with food for 7 days. Primary outcomes were safety, tolerability,
55 optimum dose and schedule. Intensive pharmacokinetic sampling was undertaken day 1 and 5 with
56 C_{min} sampling on day 3 and 7. Fourteen healthy participants were enrolled between 18th February
57 and 11th May 2021. All 14 doses were completed by 10/14 participants. Nitazoxanide was safe and
58 well tolerated with no significant adverse events. Moderate gastrointestinal disturbance (loose
59 stools) occurred in 8 participants (57.1%), with urine and sclera discolouration in 12 (85.7%) and 9
60 (64.3%) participants, respectively, without clinically significant bilirubin elevation. This was self-
61 limiting and resolved upon drug discontinuation. PBPK predictions were confirmed on day 1 but with
62 underprediction at day 5. Median C_{min} was above the *in vitro* target concentration on first dose and
63 maintained throughout. Nitazoxanide administered at 1500mg BID with food was safe and well
64 tolerated and a phase 1b/2a study is now being initiated in COVID-19 patients.

65

66 Introduction

67 Since the emergence of coronavirus-induced disease (COVID-19) in Wuhan, China in 2019, numerous
68 treatment candidates have been tested in late phase clinical trials. To date limited therapeutic
69 options [1] exist, such as steroids and IL-6 receptor blockers (tocilizumab and sarilumab) as
70 immunomodulators in severe disease, and emerging signals of efficacy of antiviral monoclonal antibody
71 therapies. Repurposing of approved drugs is in principle the fastest way to establish interventions
72 during an urgent public health crisis. This has yielded interventions for severe COVID-19, but efforts
73 to establish repurposed antiviral interventions have not been successful to date. Reasons for failure
74 are multifaceted and relate to the pharmacokinetics and pharmacodynamics of the candidate
75 antiviral drugs. In terms of pharmacokinetics, most putative repurposing drugs that have been
76 studied preclinically are not expected to reach systemic antiviral concentrations at the approved
77 dose and schedule [2]. Redundancy of the expected mechanism of action in vivo has also been
78 reported, which was driven by inadequacy of the in vitro model used to demonstrate activity. For
79 example, the primary mechanism of antiviral activity for hydroxychloroquine in Vero cells involved a
80 process for viral entry which is secondary in vivo. As such, hydroxychloroquine activity is mitigated in
81 animal models and in cells expressing TMPRSS2 [3, 4].

82 Nitazoxanide is a thiazolide FDA approved antiparasitic medicine used for the treatment of
83 cryptosporidiosis and giardiasis [5] and also has reported activity against anaerobic bacteria,
84 protozoa and several other viruses [6]. Rapid deacetylation of nitazoxanide in blood means that the
85 major systemic species of the drug in vivo is tizoxanide. Tizoxanide has been shown to exhibit similar
86 in vitro inhibitory activity to nitazoxanide for rotaviruses [7], hepatitis B and C viruses [8, 9],
87 coronaviruses other than SARS-CoV2 and noroviruses [10, 11]. It has also demonstrated in vitro
88 activity against influenza viruses [12, 13] and in a phase 2b/3 trial in uncomplicated influenza,
89 nitazoxanide demonstrated a reduction in symptoms and viral shedding at a dose of 600mg twice-
90 daily compared to placebo [14], despite these doses providing systemic concentrations that are only
91 expected to remain above the influenza in vitro target for a fraction of the dosing interval [2].
92 Similarly, several recent small clinical trials have indicated some antiviral and clinical benefits of
93 nitazoxanide but at doses that are not expected to maintain concentrations above the in vitro
94 antiviral target for the full dosing interval [15-17]. While this is encouraging, higher doses and
95 combinations are likely to be ultimately needed to maximise the antiviral activity and mitigate the
96 risk of emergence of drug resistance [18, 19]. The antiviral mechanism of action of nitazoxanide
97 against influenza involves an impact upon post-translational modification and maturation of
98 hemagglutinin [20], and a similar mechanism involving the SARS-CoV-2 spike protein was also
99 recently reported [21].

100 Other potential benefits of nitazoxanide in COVID-19 may derive from its impact upon the innate
101 immune response that potentiates the production of type 1 interferons [13, 22] and bronchodilation
102 of the airways through inhibition of TMEM16A ion channels [23]. Moreover, a recent study indicated
103 that drugs which inhibit TMEM16, like nitazoxanide, block the SARS-CoV-2 spike protein-mediated
104 syncytia formation via a mechanism independent of their antiviral activity [24]. At conventional
105 doses of 500 mg twice daily, nitazoxanide achieves C_{trough} plasma concentrations close to the in vitro
106 defined target concentration for SARS-CoV-2 [25], and exhibits antiviral activity in cell types that
107 recapitulate in vivo mechanism of replication [15]. The highest nitazoxanide dose reported to date in
108 COVID-19 clinical trials is 1000mg twice-daily, utilised in combination with another agent.

109 Published physiologically-based pharmacokinetic (PBPK) modelling, validated against nitazoxanide
110 pharmacokinetics after single doses ranging between 500 and 4000mg as well as twice daily doses of
111 0.5 and 1g, indicated doses above those already approved may provide C_{trough} above the antiviral
112 target in the majority of patients [2]. Modelling estimated that 1400mg twice-daily or 900mg three-
113 times daily will provide pulmonary exposures for the entire dosing interval above the reported in
114 vitro EC_{90} for SARS-CoV-2 in over 90% of the population. Nitazoxanide has an established safety
115 record in humans and studies showed tolerability of single oral doses up to 4000g with minimal
116 gastrointestinal side effects. In a separate study involving 16 healthy males, doses of either 500mg
117 twice-daily or 1000mg twice-daily for 7 days, the 500mg dose was well-tolerated with only mild
118 adverse events not differing significantly from the placebo [26]. The 1000mg twice-daily dose was
119 associated with an increased frequency of gastrointestinal side effects, primarily diarrhoea and
120 abdominal discomfort, but no significant changes were noted in the safety parameters and
121 laboratory tests.

122 The combination of a long-established safety track record along with its demonstrated in vitro
123 activity against coronaviruses including SARS-CoV-2, and its availability from global generic
124 manufacturers at extremely low cost, makes nitazoxanide an attractive therapeutic option for dose
125 escalation and repurposing. As such it was prioritised for evaluation at higher doses within the AGILE
126 clinical trial platform, as a potential therapeutic for mild/moderate disease.

127

128 **Methods**

129 **Study design**

130 This was a single-centre, open label, adaptive, phase 1 trial in healthy adult participants
131 (NCT04746183). This was undertaken as a candidate specific trial within AGILE; a Phase Ib/IIa
132 platform trial for evaluating new therapies for COVID-19 [www.agiletrial.net], comprising an over-
133 arching Master Protocol [27] under which sits candidate-specific trials evaluating specific
134 compounds. The study protocol was reviewed and approved by the UK Medicines and Healthcare
135 products Regulatory Agency (MHRA) and West Midlands Edgbaston Research Ethics Committee. The
136 study was coordinated by the National Institute for Health Research (NIHR) Southampton Clinical
137 Trials Unit with participants recruited into the NIHR Royal Liverpool and Broadgreen Clinical
138 Research Facility (UK).

139 **Participants**

140 Eligible participants included healthy adult males and non-pregnant and non-lactating females
141 between 18 and 75 years of age. Females of childbearing potential and males (who are sexually
142 active with female partners of childbearing potential) were required to use two effective methods of
143 contraception, one of which should be highly effective, throughout the study and for 50 days
144 (females) and 100 days (males) thereafter. Participants were included if they were confirmed to be
145 healthy in the absence of any clinically significant cardiovascular, respiratory, gastrointestinal,
146 neurological, psychiatric, metabolic, endocrine, renal, hepatic, haematological or other major
147 disorder. Specific exclusion criteria included: pregnancy or currently lactating, being in receipt of any
148 medication, including St John's Wort, known to chronically alter drug absorption or elimination
149 within 30 days prior to first dose administration. In particular, owing to the high protein binding of
150 tizoxanide; warfarin, phenytoin, amiodarone and intravenous chemotherapy were specifically
151 prohibited within 30 days or five half-lives (whichever was longer) of first dose administration and up
152 to the end of the study. Participants in receipt of any prescribed medication that required dose
153 alteration or any non-prescribed systemic or topical medication, herbal remedy or vitamin/mineral
154 supplementation within 14 days prior to the first dose administration (unless, in the opinion of the
155 investigator, it would not interfere with study procedures or compromise safety) were specially
156 excluded. Additionally, those with any clinically significant allergy or those that had previously
157 received nitazoxanide or its constituent parts within 3 months of receiving first dose. All participants
158 provided written informed consent before enrolment. The full list of inclusion and exclusion criteria
159 can be found in supplementary Table 1. The flow of participants is outlined in Figure 1.

160 **Dosing**

161 Eligible participants received 1500mg nitazoxanide orally with food, twice-daily for 7 days. Dosing
162 with food was undertaken on the inpatient unit on day 1 and day 5; the remaining dosing was
163 administered by the participants at home with instruction to eat within 30 minutes of dosing. In this
164 study we had pre-defined three dosing strategies for nitazoxanide: i) 1500 mg 12 hourly ('bd dosing')
165 which was predicted by our pharmacokinetic models to achieve the desired target concentrations,
166 plus a further two regimens of ii) 1000mg 8 hourly ('tds dosing') and iii) 1500mg in the morning,
167 2000mg in the evening ('asymmetric dosing'). A Safety Review Committee (SRC) was planned to
168 review the initial regimen (1500 mg bd) and if deemed a failure because of toxicity or failure to
169 achieve target plasma concentrations could recommended progression to the 1000mg tds and/or
170 asymmetric dose cohorts. If the SRC considered a regimen as safe with an achievement of target
171 plasma concentrations they could recommend its further investigation in a future Phase 1b/2a trial
172 in COVID-19 patients.

173 **Study procedures**

174 Viral PCR swab screening to exclude COVID-19 was performed for all participants 48-hours prior to
175 admission to the unit. General physical examination, serum chemistry and haematology sampling
176 were performed at screening, 48 hours prior to dosing, day 1 baseline, 72 hours and 120 hours post-
177 dose followed by the final study visit at day 14 post-first dose. Urinalysis was performed at
178 screening, 48 hours pre-dose, 72 hours post-dose followed by the final study visit at day 14 post-first
179 dose. Adverse events (AEs) were collected from the time of start of the first dose and throughout
180 the study period. For gastrointestinal tolerance the safety focus point was stool frequency and
181 consistency assessed according to the Bristol Stool Chart (BSC).

182 **Outcomes**

183 The primary outcome for this study was to assess safety, tolerability, optimum dose and dosing
184 schedule of nitazoxanide in healthy participants through the following parameters: AEs, general
185 physical examination, general safety assessments including ECG, vital signs, clinical laboratory
186 analysis including urinalysis, haematology and serum chemistry. Since gastrointestinal intolerance
187 was anticipated at the high doses of nitazoxanide used, participants were asked to fill in a Bristol
188 Stool Chart for the duration of assessment. The primary endpoint for this trial was safety and
189 tolerability defined by AE frequency and severity, of nitazoxanide in healthy volunteers assessed
190 over 10 days.

191 Unacceptable safety and tolerability parameters were defined as:

- 192 • A treatment emergent serious adverse event (SAE) in one subject that was considered by the
193 investigator to be related to the study drug

- 194 • Two or more adverse events, the clinical severity of which was graded by the investigator as
195 3 (severe), 4 (life threatening) or 5 (resulting in death)
- 196 • Two or more participants in a cohort required withdrawal due to elevated alanine
197 aminotransferase (ALT) levels:
- 198 ○ Asymptomatic elevation in ALT or AST to > three-times the upper limit of normal
199 (ULN), confirmed by a repeat measurement within 48 to 72 hours, accompanied by
200 either direct bilirubin level > or = to two-time ULN or International Normalised Ratio
201 (INR) > or = 1.5, confirmed with repeat measurement within 48 to 72 hours.
- 202 ○ Symptomatic elevation in ALT to >three-times ULN.
- 203 • Significant diarrhoea, defined as seven or more episodes, rated greater than or equal to five
204 on the Bristol Stool Chart (BSC), in one day for two consecutive days was seen in two or
205 more participants in a group

206

207 Additional participant withdrawal criteria included:

- 208 • Any clinically relevant signs or symptoms that, in the opinion of the investigator, warrant
209 participant withdrawal.
- 210 • QTcB prolongation to >500 milliseconds or a rise in QTcB value of >60 milliseconds
211 (whichever was lower), observed on triplicate ECGs, compared to the baseline mean QTcB.
- 212 • Positive urine drugs of abuse screen, alcohol breath test or pregnancy test result.

213 **Pharmacokinetic analysis**

214 Intensive plasma pharmacokinetic (PK) sampling for tizoxanide and tizoxanide glucuronide was
215 undertaken on day 1 and day 5. Blood samples were collected pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and
216 12h after first dose administration. Additional C_{trough} PK samples were obtained at 12-hours post-
217 dose on day 3 and 7. Tizoxanide and tizoxanide glucuronide concentrations in plasma were
218 measured using a validated liquid chromatography tandem mass spectrometry (LC-MS) method. In
219 brief, analytes were extracted from plasma by protein precipitation with 0.1% formic acid in
220 acetonitrile, centrifuged and diluted in a reconstitution solution (5 mM ammonium formate:
221 acetonitrile, 50:50 v/v) before injection onto the HPLC column. Deuterated (D_4) internal standards
222 were used and chromatographic separation was achieved using a reverse phase C_{18} column. The
223 calibration range was linear between 50-45,000 ng/mL for both analytes. As per protocol,
224 pharmacokinetic success in the trial was defined as median C_{trough} values above the 1.43 mg / L
225 derived from the in vitro EC_{90} against SARS-CoV-2.

226 The combined parent tizoxanide and tizoxanide-glucuronide metabolite dataset was fitted with a
227 parent-metabolite PK model using 1-compartment disposition for both tizoxanide and tizoxanide-
228 glucuronide, with 1st order absorption/appearance for tizoxanide. The model is similar to previous
229 parent-metabolite PK models applied for example to rifapentine [28] and a schematic and rate
230 equations are provided in supplementary figure 1. In the absence of definitive mass balance data for
231 fraction of total parent drug clearance accounting for the formation route of the glucuronide
232 metabolite, apparent CL_{met} and V_{met} parameters were estimated for the metabolite. Fitting of this
233 PK model to the observed plasma concentration data was carried out in the R programming
234 environment (v 4.0.3) [29] making use of the Pracma library [30] and lsqnonlin function for nonlinear
235 regression, treating the dataset from all participants as a naïve pool. When further data become
236 available at the current dose, this PK model can be applied using a nonlinear-mixed effects
237 population approach for characterisation of interindividual variability and potential covariate
238 relationships with PK parameters.

239 In previously published work, a physiologically based pharmacokinetic (PBPK) model was validated
240 for nitazoxanide using Simbiology (MATLAB R2019a, MathWorks Inc., Natick, MA, USA) and used to
241 inform dose selection for the current trial. [31]. Therefore, a comparison was made between the
242 observed pharmacokinetics in the trial and the a priori validated PBPK model prediction.

243 **Statistical analysis**

244 We utilised a Bayesian adaptive design to support decision making in this phase Ia study. Details are
245 provided in Supplement material. Briefly, there was uncertainty about the order of some of the
246 dosing strategies, with respect to their toxicity. To enable us to relax the assumption of monotonicity
247 of toxicity we used the Partial Ordering Continual Reassessment Method (POCRM) design proposed
248 by Wages *et al.* [32] adjusted to the AGILE setting.

249 The POCRM utilises a simple, one-parameter logistic dose-toxicity model, which describes the
250 relationship between dose-limiting toxicities (DLT) within 10 days of initiating treatment and
251 treatment dose (1500mg BD, 1000mg TID, asymmetric dosing) and includes the uncertainty about
252 orderings in the working model itself. For each possible ordering, the POCRM fits a CRM model and
253 finds the posterior probability of each ordering being the true ordering. The model that is deemed
254 the most likely one given the data observed is used for the escalation/de-escalation decisions. The
255 prior distributions for the POCRM were calibrated to maximise the proportion of correct selection
256 under the range of possible orderings and dose-toxicity scenarios within each ordering, where each
257 dose strategy considered in the study was the optimum one.

258 At the end of the cohort, the Safety Review Committee (SRC) reviewed all available safety data
259 including at least 10 days data for each participant in the cohort, including data on AEs, vital signs,
260 ECG and clinical laboratory evaluations, as well as any emerging data from other studies. Following
261 SRC review, recommendations could be to de-escalate, escalate, remain at the same dose, or
262 continue to phase Ib. A dose was deemed to be unsafe if there was a $\geq 25\%$ chance that treatment
263 was associated with a $>20\%$ risk of dose-limiting toxicities at day 10. The model recommended the
264 next dose-level according to which level is the most likely to correspond to DLT rate of 5-15%.
265 However, the SRC made the ultimate decision whether to accept that the current dose was safe and
266 met the target median C_{trough} value of 1.43 mg / L.

267 All analyses are reported according to CONSORT 2010 and ICH E9 guidelines on Statistical Principles
268 in Clinical Trials. All enrolled participants were included in both the evaluable population and the
269 safety population for analysis. Statistical analysis was undertaken in SAS version 9.4, STATA version
270 16 and R version 4.0.2. Baseline demographics and AEs are summarised using descriptive statistics.
271 The estimated DLT rates for each dose strategy and equal-tail 95% credible intervals taken from the
272 model of the most likely ordering in table 3. For active doses, we also present the probability that
273 the DLT rate falls within 5-15% (a pre-determined acceptable target range for toxicity) and the
274 probability of at least 20% toxicity (deemed as unacceptably toxic).

275 The sample size was flexible, based on the need for the study to adapt to accruing safety data.
276 Simulations to assess model operating characteristics and to calibrate priors assumed three possible
277 orderings and the same three dose strategies within each ordering, with cohorts of size twelve
278 capped at a total of 36 participants.

279 **Results**

280 Between 18th February and 11th May 2021, 14 healthy volunteers received at least one dose of
281 nitazoxanide. Of 14 participants dosed, 10/14 (71.4%) completed 7 full days of dosing (14 doses).
282 Four participants did not complete dosing as a result of a suspected QTcB prolongation occurring in
283 one participant which led to suspension of dosing in the entire cohort. 4/14 discontinued dosing
284 early; 2/4 discontinued after 6 full days (12/14 doses) and the remaining 2/4 discontinued after 1 full
285 day (2/14 doses). All 14 participants were included in the safety and PK analyses. The flow of trial
286 participants is shown in Figure 1. The demographics and clinical characteristics at baseline are
287 summarized in Table 1.

288 **Safety results**

289 Nitazoxanide was safe and well tolerated at 1500mg twice daily for 7 days with no significant
290 adverse events (Table 2). Moderate gastrointestinal (GI) disturbance was seen in 3 participants
291 (21.4%) with a further 8 participants (57.1%) experiencing mild GI symptoms (covering a spectrum of
292 nausea, bloating, constipation, diarrhoea or loose stools and/or abdominal pain). Yellow
293 discoloration of the urine and sclera was observed in 12 (85.7%) and 9 (64.3%) participants,
294 respectively, without clinically significant elevation in bilirubin. This was self-limiting and resolved
295 upon discontinuation of the drug. No grade 3 or 4 adverse events were documented.

296 Minor, self-resolving, post-dose elevation in creatine kinase (CK) was identified in 5/14 participants
297 (maximum 869 U/L at D5 post-dose, suppl table). One of the participants reported mild localised
298 myalgia without muscle tenderness at D5 (CK 508 U/L) which was recorded as an AE. All other
299 elevations were not considered clinically significant.

300 In one participant, tachycardia (HR 112bpm) developed shortly after the second dose administration
301 on day 1, with an ECG recorded 7 minutes following the second dose showing a corrected QTcB
302 (Using Bazett's formula) of 468msecs, an apparent increase of 73.5 milliseconds above the mean
303 baseline (394.5msec). Treatment was discontinued in all being dosed. Following overnight admission
304 for observation and serial ECGs, an apparent prolongation recurred at 5 hours and 44 minutes
305 following the second dose, 460 millisecs (65.5 millisecs above baseline mean, HR 87bpm) and
306 resolved fully thereafter. Independent cardiology review of all ECG's with manual QT and QTcB
307 calculations confirmed an artefactual QTcB increase due to the presence of a prominent U-wave
308 fused with the end of the T wave, causing the ECG machine to calculate the QU interval instead of
309 the QT interval. Following formal review by the trial Safety Review Committee and in consultation
310 with the UK medicines regulator, the trial (which had been temporarily suspended) was reopened at
311 the same dose level with replacement of 2 participants who discontinued dosing after only 1 full day.

312 Additional ECGs were obtained at 14 hours post first-dose on D1 and D5 for subsequent participants,
313 with no significant changes observed.

314 **Pharmacokinetics and modelling**

315 Median C_{trough} at the end of the first dose were above the in vitro-defined target concentration (EC_{90}
316 – 1.43 mg/L) and remained so throughout dosing. The simultaneous fitting of the parent-metabolite
317 pharmacokinetic model to the tizoxanide and tizoxanide glucuronide datasets is illustrated in Figure
318 2, with parameter estimates and relative standard errors in Table 4. An acceptable description of the
319 data was obtained with acceptable precision of estimates. Interindividual variability in plasma
320 exposure appears relatively wide but may reflect to some extent variability in administration times
321 for doses taken by patients at home compared to nominal dosing times. The PBPK simulated
322 tizoxanide plasma concentrations relative to the naïve pool of data from healthy individuals in this
323 study is shown over the 7days of dosing in Figure 3A. Figure 3B and 3C show the comparison of the
324 observed and simulated median pharmacokinetic profiles on day 1 and day 5, respectively. The
325 corresponding pharmacokinetic data and a numerical comparison between observed and simulated
326 C_{max} and C_{trough} is provided as Suppl. Table 4. The trial confirmed prior PBPK predictions for first
327 dose but with underprediction of exposures at day 5, with higher pharmacokinetic exposures and
328 delayed T_{max} observed clinically than predicted by the PBPK modelling. Since the PBPK model was
329 validated against the clinical data for multiple BID doses of 500mg and 1g nitazoxanide [33], where
330 no drug accumulation was observed as the days progressed, the model was not able to capture
331 appropriately the drug accumulation observed with the 1500 mg BID regimen with an increasing
332 C_{trough} from day 1 to day 5 and day 7. However, concentrations above the target (i.e. EC_{90} – 1.43
333 mg/L) were achieved on the first dose and safely maintained throughout the course.

334 **Discussion**

335 This study establishes the safety and tolerability of high-dose nitazoxanide, with food in healthy
336 adult participants. A nitazoxanide dose of 1500mg twice-daily for 7 days is safe and well-tolerated
337 and the plasma concentrations attained are expected to be sufficient to achieve the in vitro-defined
338 EC₉₀ against SARS-CoV-2 in over 90% of the population. As expected, gastrointestinal effects were
339 common (predominantly nausea, abdominal discomfort, bloating, loose stools) and at most, of
340 moderate intensity (Grade 2 discomfort sufficient to cause interference with normal activities).
341 Participants also reported yellow discolouration of sclera and bodily fluids in line with the Summary
342 of Product Characteristics (SmPC) and previous reports, and these fully resolved upon
343 discontinuation of the drug.

344 Minor elevation in CK, predominantly in the second half of the cohort, was noted in 5/14
345 participants. This was also self-resolving and not associated with muscle tenderness on physical
346 examination. We believe increased self-reported physical activity of participants, coinciding with
347 COVID-19 lockdown restrictions easing, may explain the mild CK elevations observed but ongoing
348 monitoring of CK will be undertaken as part of phase 1b in COVID-19 patients.

349 After review, the Safety Review Committee and the AGILE Independent Data Monitoring and Ethics
350 Committee agreed that these adverse events were minor. The POCRM model suggested an
351 escalation to the asymmetric regimen was safe. However, the preferred starting regimen of 1500mg
352 BD was on course to yield optimal exposure and was recommended to progress to evaluation in
353 patients with COVID-19. An AGILE phase 1b study is now being initiated in South Africa for
354 confirmatory PK analysis and tolerability in COVID-19 patients, with seamless transition into phase
355 2a.

356 Selection of the target plasma concentration was based upon an in vitro derived EC₉₀ value
357 generated in Vero cells using nitazoxanide and not tizoxanide [34]. However, further in vitro
358 experimentation conducted internationally since this original report has demonstrated similar
359 activity in lung epithelial cell models as well as activity of tizoxanide comparable to nitazoxanide
360 itself [35-37]. Furthermore, the antiviral activity has been confirmed to involve inhibition of
361 maturation of the SARS-CoV-2 spike protein [21], which is similar to the mechanism of antiviral
362 activity for influenza [38]. More recently, a separate and distinct mechanism involving blocking of
363 spike-mediated syncytia formation via interactions with TMEM16 has been reported, which may
364 moderate disease severity in parallel to the antiviral effect [24]. Target concentrations for this
365 secondary mechanism are yet to be clarified but warrant further investigation.

366 Whilst defining the optimal dose and duration of repurposed therapeutics is fundamental to later
367 trial success, it cannot be assumed that effective doses and exposures directly translate into patients
368 with COVID-19, particularly those with altered pathophysiology due to severe illness. This is a
369 limitation of all first-in-human healthy volunteer studies, within which it is always difficult to
370 generate pharmacodynamic data. The median age and lack of medical comorbidities in this healthy
371 volunteer cohort also differs from the main target population for early use of antivirals, although
372 their use in post-exposure prophylaxis and to reduce isolation requirements in low-risk groups is also
373 being considered.

374 There is an urgent unmet need for safe and effective antiviral therapeutics in early-stage
375 mild/moderate COVID-19. These are aimed at preventing progression of disease to hospitalisation
376 and death, and possibly also reducing viral transmission in community settings. Re-purposing and
377 dose escalation of nitazoxanide for COVID-19 is supported by in-vitro data, PBPK modelling and now
378 robust safety and pharmacokinetic data at the 1500mg BD dose. This dose will provide the maximum
379 potential to demonstrate antiviral activity of nitazoxanide in subsequent trials to provide a definitive
380 outcome on the utility of this drug in COVID-19.

381

382 **Study Highlights**

383 **What is the current knowledge on the topic?**

384 Nitazoxanide is an anti-parasitic medication licensed by the FDA at standard dosing (500mg BD) with
385 an established safety profile. Antiviral activity has been demonstrated for numerous viruses with in
386 vitro data demonstrating activity against SARS-CoV-2. No steady-state pharmacokinetic data are
387 available at higher doses or in COVID-19 but PBPK modelling has indicated a 1500mg BD regimen will
388 achieve required SARS-CoV-2 plasma EC₉₀ concentrations across the dosing period.

389 **What question did this study address?**

390 Is high-dose nitazoxanide safe and well-tolerated in healthy individuals and can it achieve and
391 maintain plasma antiviral concentrations predicted to be sufficient to prevent maturation of the
392 SARS-CoV-2 spike protein and therefore drive antiviral efficacy?

393 **What does this study add to our knowledge?**

394 Plasma concentrations of nitazoxanide, the major circulating form of nitazoxanide, are sufficient to
395 maintain the in vitro derived EC₉₀ and can be safely achieved in healthy individuals. The 1500mg BD
396 dose is well tolerated, with mild gastrointestinal side effects in healthy volunteers.

397 **How might this change clinical pharmacology or translational science?**

398 This phase 1a study precedes a seamless Phase 1b/2a evaluation of high dose nitazoxanide in
399 mild/moderate COVID-19 within the AGILE platform. It has provided key information on the
400 pharmacokinetic profile and tolerability at higher doses that supports its evaluation in COVID-19
401 patients and potential use as an antiviral in other diseases. These doses will give the maximal
402 opportunity to achieve antiviral concentrations for SARS-CoV-2 but the utility of nitazoxanide for
403 COVID-19 can only be determined in subsequent trials in patients.

404

405

406 **Acknowledgements**

407 Sara Yeats, Emma Tilt, Emma Wrixon, Andrea Corkhill and Catherine Simpson

408 **Author contributions**

409 Study design: SK, GG, TJ, PM, DL, MJ, RJF, GS, SE, TF, AO, LW

410 Data analysis and interpretation: SK, GG, TJ, SE, GS, KT, PM, HP, ML

411 Clinical conduct: LW

412 Clinical assessment and data collection: LW, RL, RC, TR, TF, RJF, MF

413 Pharmacovigilance: KF

414 Digital data collection and data management: RW, LJ

415 Bioanalysis: CH, SK, Laura Else, Sujan Dilly-Penchala, Alieu Amara

416 Study management and execution: HR, CW, KM, IE

417 Study monitoring: PM

418 PBPK modelling: AO, RR, HP

419 Primary manuscript writing: LW, TF, SK, AO, GS

420 All authors contributed to the final version of the manuscript.

421

422

423

424

425

426

427

428

429 Figure 1: CONSORT Diagram

430 Figure 2: Simultaneous 1-compartment, 1st order absorption parent-metabolite PK model fitting to
431 naïve pooled tizoxanide (parent) and tizoxanide-glucuronide (metabolite) plasma concentration
432 data. The red line represents the in vitro derived EC₉₀ against SARS-CoV-2 (1.43 mg/L).

433 Figure 3. Comparison of PBPK simulated and observed tizoxanide plasma concentrations. A)
434 comparison of median (standard deviation) simulated concentrations (blue) against the naïve pool of
435 plasma concentration in healthy individuals. B) Comparison of observed and simulated median (95%
436 CI) tizoxanide plasma concentrations following the first dose. C) Comparison of observed and
437 simulated median (95% CI) tizoxanide plasma concentrations on day 5. The red line represents the in
438 vitro derived EC₉₀ against SARS-CoV-2 (1.43 mg/L; 5.4 micromolar).

439

440 Table 1. Participant demographics and characteristics

Characteristics	Statistic	Nitazoxanide (1500mg twice-daily, n=14)
Age	Median (range)	25 (19-53)
Sex	Male/female %	35.7%/64.3%
Ethnicity	White-English/Welsh/Scottish/Northern Irish/British	9 (64.3%)
	Any other White background	3 (21.4%)
	Any other Asian background	2 (14.3%)
Body weight (kg)	Median (range)	65.6 (61.2 – 96.3)
BMI (kg/m ²)	Median (range)	23.9 (19.3 – 30.8)

441

442 Table 2 AEs and serious AEs

Adverse event (all grades 1 or 2)	Nitazoxanide (1500mg BID) (n=14)
Urine Discoloration	12 (85.7%)
Yellow Sclera	9 (64.3%)
Nausea	7 (50.0%)
Abdominal Pain	6 (42.9%)
Diarrhoea	5 (35.7%)
Loose Stools	3 (21.4%)
Myalgia	3 (21.4%)
Bloating	2 (14.3%)
Headache	2 (14.3%)
Right Corneal Irritation	1 (7.1%)
Constipation	1 (7.1%)
Flatulence	1 (7.1%)
Fever	1 (7.1%)
Flu Like Symptoms	1 (7.1%)
Loss Of Appetite	1 (7.1%)
Non-Cardiac Chest Pain	1 (7.1%)
Fall	1 (7.1%)
Umbilical Hernia	1 (7.1%)
Dizziness	1 (7.1%)
Lethargy	1 (7.1%)
Dysuria	1 (7.1%)
Irregular Menstruation	1 (7.1%)
Semen Discoloration	1 (7.1%)

Vaginal Discharge	1 (7.1%)
Laryngeal Inflammation	1 (7.1%)
Blister On Abdomen	1 (7.1%)
Hypotension	1 (7.1%)
Abdominal Gas (Rumbling)	1 (7.1%)
Elevated creatine kinase	1 (7.1%)
Heavy Sensation To Eyes	1 (7.1%)
Leg Pain/Stiffness	1 (7.1%)
Mouth Ulcer	1 (7.1%)
Musculoskeletal Pain (Elbow)	1 (7.1%)
Musculoskeletal Pain (Hip)	1 (7.1%)
Other - Stomach Cramps	1 (7.1%)
Rash	1 (7.1%)
Reduced Appetite	1 (7.1%)
Shortness Of Breath	1 (7.1%)
Skin Discolouration	1 (7.1%)
Stye (Right Eye)	1 (7.1%)
Yellow Semen	1 (7.1%)
Serious adverse event (grade 3)	
Electrocardiogram QT Corrected Interval Prolonged	1 (7.1%)

444 Table 3: Estimated toxicity for Nitazoxanide up to day 10 from the POCRM model (for ordering 3)

Dose level	Estimated DLT rate (95% Credible interval)	Target dose probability (5-15% DLT rate) (%)	Probability of being overly toxic (toxicity > 20%) (%)
1500mg BID	2.1% (0.0% - 14.4%)	11.8%	0.9%
1000mg TID	0.2% (0.0% - 2.1%)	0.6%	0.0%
Asymmetric	9.0% (0.0% - 36.2%)	26.6%	15.2%

445

446 Table 4. Parameter estimates for simultaneous parent-metabolite PK model fitting to tizoxanide and
447 tizoxanide glucuronide plasma concentration data.

448

	CL_{TIZ}/F_{TIZ} (L/h)	V_{TIZ}/F_{TIZ} (L)	KA (h ⁻¹)	$CL_{MET}/(F_{TIZ} * F_{MET})$ (L/h)	$V_{MET}/(F_{TIZ} * F_{MET})$ (L/h)
Parameter Estimate	3.95	64.99	0.45	5.88	12.71
% RSE*	3.64	8.15	14.20	3.70	12.67

449

450 References

- 451 1. Thorlund, K., et al., *A real-time dashboard of clinical trials for COVID-19*. Lancet Digit Health, 2020. **2**(6): p. e286-e287.
- 452
- 453 2. Rajoli, R.K.R., et al., *Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis*. Br J Clin Pharmacol, 2021. **87**(4): p. 2078-2088.
- 454
- 455 3. Hoffmann, M., et al., *Chloroquine does not inhibit infection of human lung cells with SARS-*
- 456 *CoV-2*. Nature, 2020. **585**(7826): p. 588-590.
- 457 4. Rosenke, K., et al., *Hydroxychloroquine Proves Ineffective in Hamsters and Macaques*
- 458 *Infected with SARS-CoV-2*. bioRxiv, 2020.
- 459 5. C., W., *Antiparasitic agents*, in *Principles and practice of paediatric infectious diseases*, L. S,
- 460 Editor. 2012: London. p. 1518-1543.
- 461 6. Keiser J, U.J., *The drugs we have and the drugs we need against major helminth infections.*,
- 462 in *Advances in parasitology*, Z. N, Editor. 2010, Academic Press. p. 197-230.
- 463 7. Rossignol, J.F. and Y.M. El-Gohary, *Nitazoxanide in the treatment of viral gastroenteritis: a*
- 464 *randomized double-blind placebo-controlled clinical trial*. Aliment Pharmacol Ther, 2006.
- 465 **24**(10): p. 1423-30.
- 466 8. Korba, B.E., et al., *Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of*
- 467 *hepatitis B virus and hepatitis C virus replication*. Antiviral Res, 2008. **77**(1): p. 56-63.
- 468 9. Korba, B.E., et al., *Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide*.
- 469 *Antimicrob Agents Chemother*, 2008. **52**(11): p. 4069-71.
- 470 10. Dang, W., et al., *Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with*
- 471 *Ribavirin by Activation of Cellular Antiviral Response*. Antimicrob Agents Chemother, 2018.
- 472 **62**(11).
- 473 11. Dang, W., et al., *Opposing Effects of Nitazoxanide on Murine and Human Norovirus*. J Infect
- 474 Dis, 2017. **216**(6): p. 780-782.
- 475 12. Koszalka, P., D. Tilmanis, and A.C. Hurt, *Influenza antivirals currently in late-phase clinical*
- 476 *trial*. Influenza Other Respir Viruses, 2017. **11**(3): p. 240-246.
- 477 13. Rossignol, J.F., *Nitazoxanide: a first-in-class broad-spectrum antiviral agent*. Antiviral Res,
- 478 2014. **110**: p. 94-103.
- 479 14. Haffizulla, J., et al., *Effect of nitazoxanide in adults and adolescents with acute*
- 480 *uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial*.
- 481 *Lancet Infect Dis*, 2014. **14**(7): p. 609-18.
- 482 15. Rocco, P.R.M., et al., *Early use of nitazoxanide in mild COVID-19 disease: randomised,*
- 483 *placebo-controlled trial*. Eur Respir J, 2021. **58**(1).
- 484 16. Blum, V.F., et al., *Nitazoxanide superiority to placebo to treat moderate COVID-19 - A Pilot*
- 485 *proof of concept randomized double-blind clinical trial*. EclinicalMedicine, 2021: p. 100981.
- 486 17. Rossignol JF, M.C., Oaks JB, Bostick G, Vora KN, Fulgencio J, Mogelnicki D, Brechot C,
- 487 Vanguard Study Group, *Early treatment with nitazoxanide prevents worsening of mild and*
- 488 *moderate COVID-19 and subsequent hospitalization*. medRxiv Preprint, 2021.
- 489 18. Hiscox, J.A., et al., *Shutting the gate before the horse has bolted: is it time for a conversation*
- 490 *about SARS-CoV-2 and antiviral drug resistance?* J Antimicrob Chemother, 2021.
- 491 19. Rannard, S.P., T.O. McDonald, and A. Owen, *Chasing COVID-19 chemotherapeutics without*
- 492 *putting the cart before the horse*. Br J Clin Pharmacol, 2020.
- 493 20. Rossignol, J.F., *Thiazolides: a new class of antiviral drugs*. Expert Opin Drug Metab Toxicol,
- 494 2009. **5**(6): p. 667-74.
- 495 21. Riccio A, S.S., Rossi A, Piacentini S, Rossignol J, Santoro MG., *Impairment of SARS-CoV-2 spike*
- 496 *glycoprotein maturation and fusion activity by the broad-spectrum anti-infective drug*
- 497 *nitazoxanide*. bioRxiv Preprint server, 2021.
- 498 22. Trabattoni, D., et al., *Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV*
- 499 *Replication*. Sci Rep, 2016. **6**: p. 27148.

- 500 23. Miner, K., et al., *Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are*
501 *Potent TMEM16A Antagonists That Fully Bronchodilate Airways*. *Front Pharmacol*, 2019. **10**:
502 p. 51.
- 503 24. Braga, L., et al., *Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced*
504 *syncytia*. *Nature*, 2021. **594**(7861): p. 88-93.
- 505 25. Arshad, U., et al., *Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on*
506 *Plasma and Target Site Concentrations Derived from their Established Human*
507 *Pharmacokinetics*. *Clin Pharmacol Ther*, 2020. **108**(4): p. 775-790.
- 508 26. Stockis, A., et al., *Nitazoxanide pharmacokinetics and tolerability in man during 7 days*
509 *dosing with 0.5 g and 1 g b.i.d*. *Int J Clin Pharmacol Ther*, 2002. **40**(5): p. 221-7.
- 510 27. Griffiths, G., et al., *AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II*
511 *Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate*
512 *Agents for the Treatment of COVID-19: A structured summary of a study protocol for a*
513 *randomised platform trial*. *Trials*, 2020. **21**(1): p. 544.
- 514 28. Savic, R.M., et al., *Population pharmacokinetics of rifapentine and desacetyl rifapentine in*
515 *healthy volunteers: nonlinearities in clearance and bioavailability*. *Antimicrob Agents*
516 *Chemother*, 2014. **58**(6): p. 3035-42.
- 517 29. Team, R.C., *R: A language and environment for statistical computing*. *R Foundation for*
518 *Statistical Computing, Vienna, Austria*. <https://www.R-project.org/>. 2020.
- 519 30. Borchers, H.W., *pracma: Practical Numerical Math Functions*. *R package version 2.2.9*.
520 <https://CRAN.R-project.org/package=pracma>. 2019.
- 521 31. Rajoli, R.K.R., et al., *Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or*
522 *chemoprophylaxis*. *British Journal of Clinical Pharmacology*, 2021. **87**(4): p. 2078-2088.
- 523 32. Wages, N.A., M.R. Conaway, and J. O'Quigley, *Continual reassessment method for partial*
524 *ordering*. *Biometrics*, 2011. **67**(4): p. 1555-63.
- 525 33. Stockis, A., et al., *Nitazoxanide pharmacokinetics and tolerability in man during 7 days*
526 *dosing with 0.5 g and 1 g b.i.d*. *International Journal of Clinical Pharmacology and*
527 *Therapeutics*, 2002. **40**(5): p. 221-227.
- 528 34. Wang, M., et al., *Remdesivir and chloroquine effectively inhibit the recently emerged novel*
529 *coronavirus (2019-nCoV) in vitro*. *Cell Res*, 2020. **30**(3): p. 269-271.
- 530 35. Cao, J., J.C. Forrest, and X. Zhang, *A screen of the NIH Clinical Collection small molecule*
531 *library identifies potential anti-coronavirus drugs*. *Antiviral Res*, 2015. **114**: p. 1-10.
- 532 36. Bobrowski, T., et al., *Discovery of Synergistic and Antagonistic Drug Combinations against*
533 *SARS-CoV-2 In Vitro*. *bioRxiv*, 2020.
- 534 37. Portal, N.N.C.f.A.T.S.O.D. *Nitazoxanide*. 2020 [cited 2021 20/07/2021]; Available from:
535 <https://opendata.ncats.nih.gov/covid19/databrowser?q=Nitazoxanide>.
- 536 38. Rossignol, J.F., et al., *Thiazolidines, a new class of anti-influenza molecules targeting viral*
537 *hemagglutinin at the post-translational level*. *J Biol Chem*, 2009. **284**(43): p. 29798-808.




Figure 1: CONSORT Diagram




Figure 2: Simultaneous 1-compartment, 1st order absorption parent-metabolite PK model fitting to naïve pooled tizoxanide (parent) and tizoxanide-glucuronide (metabolite) plasma concentration data. The red line represents the in vitro derived EC₉₀ against SARS-CoV-2 (1.43 mg/L).




Figure 3. Comparison of PBPK simulated and observed tizoxanide plasma concentrations. A) comparison of median (standard deviation) simulated concentrations (blue) against the naïve pool of plasma concentration in healthy individuals. B) Comparison of observed and simulated median (95% CI) tizoxanide plasma concentrations following the first dose. C) Comparison of observed and simulated median (95% CI) tizoxanide plasma concentrations on day 5. The red line represents the in vitro derived EC_{90} against SARS-CoV-2 (1.43 mg/L; 5.4 micromolar).